Drug Shortage Report for RAPAMUNE
| Report ID | 181170 |
| Drug Identification Number | 02247111 |
| Brand name | RAPAMUNE |
| Common or Proper name | RAPAMUNE |
| Company Name | PFIZER CANADA ULC |
| Market Status | MARKETED |
| Active Ingredient(s) | SIROLIMUS |
| Strength(s) | 1MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL ORAL |
| Packaging size | 100's |
| ATC code | L04AA |
| ATC description | IMMUNOSUPPRESSANTS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2023-01-13 |
| Estimated end date | 2023-02-24 |
| Actual end date | 2023-02-07 |
| Shortage status | Resolved |
| Updated date | 2023-02-10 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 17300 TRANS-CANADA HIGHWAY KIRKLAND, QUEBEC CANADA H9J 2M5 |
| Company contact information | Customer Service / service à la clientèle : 1-888-999-8750 Email / courriel: PharmaCustomerServiceDept@pfizer.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v4 | 2023-02-10 | French | Compare |
| v3 | 2023-02-10 | English | Compare |
| v2 | 2023-01-16 | French | Compare |
| v1 | 2023-01-16 | English | Compare |
Showing 1 to 4 of 4